Daewoong (003090) - Total Assets
Based on the latest financial reports, Daewoong (003090) holds total assets worth ₩3.10 Trillion KRW (≈ $2.10 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 003090 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Daewoong - Total Assets Trend (2000–2024)
This chart illustrates how Daewoong's total assets have evolved over time, based on quarterly financial data. Explore Daewoong long-term investment intensity to see how much of total assets are deployed in long-term investments.
Daewoong - Asset Composition Analysis
Current Asset Composition (December 2024)
Daewoong's total assets of ₩3.10 Trillion consist of 35.1% current assets and 64.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.0% |
| Accounts Receivable | ₩204.17 Billion | 7.5% |
| Inventory | ₩389.98 Billion | 14.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩293.36 Billion | 10.8% |
| Goodwill | ₩62.50 Billion | 2.3% |
Asset Composition Trend (2000–2024)
This chart illustrates how Daewoong's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Daewoong.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Daewoong's current assets represent 35.1% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 7.0% of total assets in 2024, up from 6.5% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is inventory at 14.3% of total assets.
Daewoong Competitors by Total Assets
Key competitors of Daewoong based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Daewoong - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.44 | 1.48 | 2.27 |
| Quick Ratio | 0.86 | 0.86 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩342.03 Billion | ₩290.74 Billion | ₩468.58 Billion |
Daewoong - Advanced Valuation Insights
This section examines the relationship between Daewoong's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 15.3% |
| Total Assets | ₩2.72 Trillion |
| Market Capitalization | $497.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Daewoong's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Daewoong's assets grew by 15.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Daewoong (2000–2024)
The table below shows the annual total assets of Daewoong from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.72 Trillion ≈ $1.84 Billion |
+15.32% |
| 2023-12-31 | ₩2.36 Trillion ≈ $1.60 Billion |
+9.28% |
| 2022-12-31 | ₩2.16 Trillion ≈ $1.46 Billion |
+11.65% |
| 2021-12-31 | ₩1.93 Trillion ≈ $1.31 Billion |
+5.23% |
| 2020-12-31 | ₩1.84 Trillion ≈ $1.25 Billion |
+10.15% |
| 2019-12-31 | ₩1.67 Trillion ≈ $1.13 Billion |
+4.77% |
| 2018-12-31 | ₩1.59 Trillion ≈ $1.08 Billion |
+2.78% |
| 2017-12-31 | ₩1.55 Trillion ≈ $1.05 Billion |
+5.58% |
| 2016-12-31 | ₩1.47 Trillion ≈ $994.36 Million |
+18.11% |
| 2015-12-31 | ₩1.24 Trillion ≈ $841.89 Million |
+22.91% |
| 2014-12-31 | ₩1.01 Trillion ≈ $684.96 Million |
+12.49% |
| 2013-12-31 | ₩898.47 Billion ≈ $608.88 Million |
+76.44% |
| 2012-12-31 | ₩509.22 Billion ≈ $345.09 Million |
+6.77% |
| 2011-12-31 | ₩476.95 Billion ≈ $323.23 Million |
-38.07% |
| 2010-12-31 | ₩770.12 Billion ≈ $521.90 Million |
+9.01% |
| 2009-12-31 | ₩706.44 Billion ≈ $478.74 Million |
+3.31% |
| 2008-12-31 | ₩683.79 Billion ≈ $463.39 Million |
+26.64% |
| 2007-12-31 | ₩539.93 Billion ≈ $365.91 Million |
+19.33% |
| 2006-12-31 | ₩452.46 Billion ≈ $306.62 Million |
+16.90% |
| 2005-12-31 | ₩387.05 Billion ≈ $262.30 Million |
+14.10% |
| 2004-12-31 | ₩339.21 Billion ≈ $229.88 Million |
+6.55% |
| 2003-12-31 | ₩318.37 Billion ≈ $215.76 Million |
+0.04% |
| 2002-12-31 | ₩318.26 Billion ≈ $215.68 Million |
-7.31% |
| 2001-12-31 | ₩343.38 Billion ≈ $232.70 Million |
+0.95% |
| 2000-12-31 | ₩340.15 Billion ≈ $230.52 Million |
-- |
About Daewoong
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Phar… Read more